Gujarat Kidney And Super Speciality Limited
Promoter holding in Gujarat Kidney And Super Speciality Limited has stayed unchanged at 71.45% for the last 5 quarters on record (since Sep 2025).
By quarter
Quarter by quarter
| Quarter | Promoters | Public |
|---|---|---|
| Sep '26 | 71.45%=0.00 | 28.55%=0.00 |
| Jun '26 | 71.45%=0.00 | 28.55%=0.00 |
| Mar '26 | 71.45%=0.00 | 28.55%=0.00 |
| Dec '25 | 71.45%=0.00 | 28.55%=0.00 |
| Sep '25 | 71.45% | 28.55% |
Compared with similar companies
Promoter holding in Gujarat Kidney And Super Speciality Limited is higher than 85% of companies in the Healthcare sector in India.
| Company | Promoters |
|---|---|
| Gujarat Kidney And Super Speciality Limited | 71.45% |
| Amrutanjan Health Care Limited | 46.52% |
| Jagsonpal Pharmaceuticals Limited | 69.05% |
| Suraksha Diagnostic Limited | 49.10% |
| Fermenta Biotech Limited | 64.09% |
| Anlon Healthcare Limited | 52.68% |
Similar-sized companies in the same sector, latest quarter on record.
Questions
What is Gujarat Kidney And Super Speciality Limited's promoter holding?
Promoters held 71.45% of Gujarat Kidney And Super Speciality Limited as of 30 Sep 2026, and the public held 28.55%.
Has Gujarat Kidney And Super Speciality Limited's promoter holding increased?
No, it was unchanged in the quarter to Sep 2026.
Are any promoter shares of Gujarat Kidney And Super Speciality Limited pledged?
No promoter shares are recorded as pledged.
How does Gujarat Kidney And Super Speciality Limited's promoter holding compare with similar companies?
Promoter holding in Gujarat Kidney And Super Speciality Limited is higher than 85% of companies in the Healthcare sector in India. A higher or lower promoter holding is not good or bad by itself.
From the company's quarterly shareholding filings. "Public" includes institutions (foreign and domestic) and individual investors; a split by investor type is planned. ▲/▼ shows the change from the previous quarter, in percentage points. PositoAI is for research and education only and is not investment advice.